Regulatory Environment in the US

The regulatory environment in the US for pharmaceutical and biological products is primarily overseen by the U.S. Food and Drug Administration (FDA). The regulatory framework covers drug development, clinical investigations, marketing approval, manufacturing, labelling, safety monitoring and other activities throughout the product lifecycle.

Requirements arise from federal laws, FDA regulations in the Code of Federal Regulations (CFR), and applicable FDA guidance. The specific regulatory pathway depends on factors such as the type of product, stage of development and activity being conducted.

Role of the FDA

The FDA is responsible for protecting public health by regulating products within its jurisdiction, including human drugs and biological products.

Within the FDA, different centres have responsibilities for particular product categories. The Center for Drug Evaluation and Research (CDER) primarily regulates human drugs, while the Center for Biologics Evaluation and Research (CBER) regulates biological products within its jurisdiction.

FDA responsibilities include reviewing regulatory submissions, monitoring product safety, establishing regulatory requirements, conducting inspections and taking regulatory action when applicable requirements are not met.

More information about FDA’s responsibilities and regulated products is available from the U.S. Food and Drug Administration (FDA).

Investigational New Drug Applications and Clinical Trials

Before an investigational drug can generally be administered to human participants in the United States, an Investigational New Drug (IND) application must be in effect unless an applicable exemption applies.

An IND provides FDA with information concerning areas such as nonclinical studies, manufacturing and controls, clinical protocols and investigator information.

Clinical investigations must also comply with applicable requirements concerning Institutional Review Boards (IRBs), informed consent, sponsor and investigator responsibilities, safety reporting, records and inspections.

FDA may place a clinical investigation on clinical hold when applicable regulatory criteria are met.

For a more detailed overview of the development and marketing pathways, see IND and NDA Applications in the US.

Marketing Applications

Following completion of an appropriate development programme, a sponsor may seek FDA approval to market a product.

For new drugs, the applicant generally submits a New Drug Application (NDA). Biological products subject to licensure are generally submitted through a Biologics License Application (BLA).

FDA evaluates evidence concerning safety, effectiveness and product quality, together with proposed labelling and other required information, before determining whether the applicable standards for approval have been met.

Generic Drugs

Generic drug products are generally approved through an Abbreviated New Drug Application (ANDA).

Rather than repeating the full clinical development programme conducted for the reference product, an ANDA relies on the FDA’s previous findings for the reference listed drug and must satisfy applicable requirements, including demonstrating bioequivalence where required.

The generic product must also meet applicable standards for identity, strength, quality, purity and performance.

Pharmaceutical Quality and Current Good Manufacturing Practice

Drug manufacturers must comply with applicable Current Good Manufacturing Practice (CGMP) requirements.

CGMP requirements help ensure that drug products are consistently manufactured and controlled according to appropriate quality standards. They address areas such as manufacturing facilities, equipment, production and process controls, laboratory controls, records and quality systems.

FDA conducts inspections and other regulatory activities to assess compliance with applicable manufacturing requirements.

Post-Marketing Safety Surveillance

FDA continues to monitor medicinal products after approval.

Manufacturers and other regulated entities have applicable post-marketing safety reporting responsibilities. FDA also receives and evaluates safety information from healthcare professionals, patients and other sources.

Emerging safety information can lead to regulatory actions such as labelling changes, safety communications, additional studies or other risk-management measures when appropriate.

Labelling and Prescription Drug Promotion

FDA regulates prescription-drug labelling and promotional communications within its jurisdiction.

Approved labelling communicates information such as indications, dosage and administration, contraindications, warnings and precautions, adverse reactions and other information necessary for appropriate product use.

Prescription-drug promotional communications must comply with applicable requirements and must not be false or misleading.

Pediatric Drug Development

U.S. legislation establishes specific mechanisms concerning the study of drugs and biological products in pediatric populations.

Depending on the product and development programme, pediatric studies may be required or may qualify for applicable waivers or deferrals. Other statutory provisions provide incentives for certain voluntary pediatric studies requested by FDA.

Pediatric regulatory requirements should therefore be evaluated as part of the overall development strategy rather than treated simply as an optional extension of adult development.

Orphan Drug Development

The Orphan Drug Act provides incentives intended to encourage development of products for rare diseases or conditions.

A sponsor may request orphan-drug designation for a qualifying drug or biological product. Designation can provide development incentives, while applicable statutory requirements determine eligibility for orphan-drug exclusivity following approval.

Orphan designation itself does not constitute FDA marketing approval.

Electronic Regulatory Submissions

Electronic submissions are an important part of the current U.S. regulatory environment.

FDA uses the electronic Common Technical Document (eCTD) as the standard format for many regulatory submissions to CDER and CBER. Applicable technical specifications and submission requirements depend on the submission type and regulatory context.

Sponsors and applicants should follow current FDA electronic-submission requirements when preparing regulatory applications.

Regulatory Environment in the US Across the Product Lifecycle

The regulatory environment in the US extends across the product lifecycle, from early drug development and clinical investigation through marketing approval, manufacturing and post-marketing surveillance.

The applicable requirements evolve as a product progresses through its lifecycle. Sponsors and manufacturers must therefore maintain appropriate regulatory, quality and safety systems and remain informed about changes to legislation, regulations, guidance and FDA technical requirements.

Understanding the regulatory environment in the US helps clinical-research and regulatory-affairs professionals identify the requirements that apply at each stage of pharmaceutical development and commercialisation.

You may be interested in the programs below: